HK1170429A1 - Alpha aminoamide derivatives useful in the treatment of cognitive disorders - Google Patents

Alpha aminoamide derivatives useful in the treatment of cognitive disorders

Info

Publication number
HK1170429A1
HK1170429A1 HK12111289.3A HK12111289A HK1170429A1 HK 1170429 A1 HK1170429 A1 HK 1170429A1 HK 12111289 A HK12111289 A HK 12111289A HK 1170429 A1 HK1170429 A1 HK 1170429A1
Authority
HK
Hong Kong
Prior art keywords
treatment
cognitive disorders
derivatives useful
aminoamide derivatives
alpha
Prior art date
Application number
HK12111289.3A
Other languages
English (en)
Chinese (zh)
Inventor
Patricia Salvati
Stefano Rossetti
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of HK1170429A1 publication Critical patent/HK1170429A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12111289.3A 2006-06-15 2012-11-08 Alpha aminoamide derivatives useful in the treatment of cognitive disorders HK1170429A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06012352A EP1870097A1 (en) 2006-06-15 2006-06-15 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
HK1170429A1 true HK1170429A1 (en) 2013-03-01

Family

ID=37103353

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111289.3A HK1170429A1 (en) 2006-06-15 2012-11-08 Alpha aminoamide derivatives useful in the treatment of cognitive disorders

Country Status (26)

Country Link
US (1) US8741957B2 (ja)
EP (4) EP1870097A1 (ja)
JP (2) JP2009539908A (ja)
KR (1) KR20090018817A (ja)
CN (2) CN101466366A (ja)
AR (1) AR061505A1 (ja)
AU (1) AU2007260239B2 (ja)
BR (1) BRPI0712994A2 (ja)
CA (1) CA2655243C (ja)
CY (1) CY1116699T1 (ja)
DK (1) DK2029130T3 (ja)
EA (1) EA018006B1 (ja)
ES (1) ES2549113T3 (ja)
HK (1) HK1170429A1 (ja)
HR (1) HRP20151026T1 (ja)
HU (1) HUE026484T2 (ja)
IL (1) IL195906A (ja)
ME (1) ME02343B (ja)
MX (1) MX2008016017A (ja)
NZ (1) NZ573565A (ja)
PL (1) PL2029130T3 (ja)
PT (1) PT2029130E (ja)
RS (1) RS54324B1 (ja)
SI (1) SI2029130T1 (ja)
TW (1) TWI494293B (ja)
WO (1) WO2007144153A2 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457724T1 (de) * 2003-08-25 2010-03-15 Newron Pharm Spa Alpha-aminoamid derivate zur verwendung als anti- inflammatorische wirkstoffe
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
CN101472880B (zh) 2006-06-19 2013-04-24 纽朗制药有限公司 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
MX2009013119A (es) 2007-06-15 2010-03-04 Newron Pharm Spa Derivados de 2-[2-(fenil)etilamino]alcanamida sustituidos y su uso como moduladores del canal de sodio y/o potasio.
BRPI0821026A2 (pt) 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
WO2011055383A2 (en) 2009-11-06 2011-05-12 Lyka Labs Limited Intranasal delivery to improve the performance of children suffering from dyslexia
US8255838B2 (en) * 2010-01-15 2012-08-28 Synopsys, Inc. Etch-aware OPC model calibration by using an etch bias filter
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
DK2563355T3 (en) 2010-04-27 2016-09-12 Newron Pharm Spa A process for the preparation of ralfinamide-methanesulphonate or R-enantiomers thereof.
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
ES2426539B1 (es) * 2012-04-18 2014-09-09 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
KR101420218B1 (ko) * 2012-06-13 2014-07-17 이우일 생리적안정도 측정 시스템 및 그 방법
CN104546747A (zh) * 2014-11-20 2015-04-29 美吉斯制药（厦门）有限公司 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法
CN105456214A (zh) * 2015-12-30 2016-04-06 蔡惠文 甲磺酸沙芬酰胺片
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
US11090303B2 (en) * 2018-05-15 2021-08-17 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
WO2020234275A1 (en) * 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
US20240277282A1 (en) * 2023-02-17 2024-08-22 Rowan University Automated detection of cognitive conditions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
DE58905201D1 (de) 1988-03-01 1993-09-16 Birkmayer Walther Mittel zur behandlung des parkinson-syndroms.
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
AU672401B2 (en) * 1992-05-27 1996-10-03 Merrell Dow Pharmaceuticals Inc. Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatement of Alzheimer's disease
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
DK0828513T3 (da) 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
MXPA00004919A (es) * 1997-11-21 2002-10-17 Euro Celtique Sa 2-aminoacetamidas sustituidas y uso de las mismas.
GB9727521D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
AU761457B2 (en) 1998-01-12 2003-06-05 Deborah Wenzel An additive composition also used as a fuel composition comprising water soluble alcohols
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
GB0419199D0 (en) * 2004-08-27 2004-09-29 Curidium Ltd Methods of diagnosis
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Also Published As

Publication number Publication date
TWI494293B (zh) 2015-08-01
EP2977046A1 (en) 2016-01-27
JP2013155186A (ja) 2013-08-15
SI2029130T1 (sl) 2015-11-30
TW200808696A (en) 2008-02-16
CY1116699T1 (el) 2017-03-15
RS54324B1 (en) 2016-02-29
WO2007144153A3 (en) 2008-03-13
NZ573565A (en) 2013-01-25
EP2343064A1 (en) 2011-07-13
HUE026484T2 (en) 2016-06-28
ME02343B (me) 2016-06-20
CN102512406B (zh) 2015-01-07
US20100016437A1 (en) 2010-01-21
AU2007260239B2 (en) 2012-08-30
AR061505A1 (es) 2008-09-03
WO2007144153A2 (en) 2007-12-21
AU2007260239A1 (en) 2007-12-21
PL2029130T3 (pl) 2016-01-29
EA200802306A1 (ru) 2009-06-30
HRP20151026T1 (hr) 2015-10-23
PT2029130E (pt) 2015-10-28
IL195906A0 (en) 2009-09-01
MX2008016017A (es) 2009-01-16
EP1870097A1 (en) 2007-12-26
CN101466366A (zh) 2009-06-24
BRPI0712994A2 (pt) 2012-03-27
CN102512406A (zh) 2012-06-27
EA018006B1 (ru) 2013-04-30
EP2029130B1 (en) 2015-08-19
JP2009539908A (ja) 2009-11-19
US8741957B2 (en) 2014-06-03
JP6119068B2 (ja) 2017-04-26
KR20090018817A (ko) 2009-02-23
CA2655243C (en) 2015-06-02
EP2029130A2 (en) 2009-03-04
IL195906A (en) 2016-02-29
DK2029130T3 (en) 2015-11-16
ES2549113T3 (es) 2015-10-23
CA2655243A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
HK1170429A1 (en) Alpha aminoamide derivatives useful in the treatment of cognitive disorders
HK1126212A1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
EP1957462A4 (en) NEW 2-AMINO-HETEROCYCLES USEFUL FOR THE TREATMENT OF ABETA-RELATED DISEASES
ZA200810756B (en) Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
GB0611240D0 (en) The treatment of increased sebum production
HK1146221A1 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
EP2004216A4 (en) AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
HK1139855A1 (en) Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders
GB0611241D0 (en) The treatment of increased sebum production
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
IL198134A (en) A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
AP2656A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
EP1942911A4 (en) THERAPEUTIC MOLECULES AND USES THEREOF
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
HK1145282A1 (en) Treatment of sleep disorders
IL198479A0 (en) Methods for screening for therapeutic molecules and use of the molecules therefrom
GB0602857D0 (en) The treatment of sialorrhoea
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
GB0609794D0 (en) The treatment of inflammatory disorders and pain